

## **-DRAFT-**

**INDIAN ACADEMY OF PEDIATRICS**  
Kailas Darshan, Kennedy Bridge, Mumbai-400007

**Minutes of the meeting of the IAP Advisory Committee on Vaccines & Immunization Practices (ACVIP) of Indian Academy of Pediatrics held on 3<sup>rd</sup> & 4<sup>th</sup> August at The Umrao Resort, Near Rajokri crossing, New Delhi from 10.00 am onwards.**

The following IAP members were present at the meeting:

Chair: Dr. C.P. Bansal  
Co-chair - Dr Rohit C Agrawal  
Co-chair – Dr. Vijay N. Yewale  
Convener - Dr Vipin M Vashishtha  
Coordinator: Dr. Sailesh Gupta  
Member – Dr Sashi Vani  
Member – Dr A.K. Patwari  
Member – Dr Ajay Kalra  
Member- Dr. Anuradha Bose  
Consultant- Dr Naveen Thacker  
Consultant- Dr V.G. Ramachandaran  
Consultant- Dr Ajay Gambhir  
Rapporteur: Dr. Panna Choudhury

Following member requested leave of absence:

Member – Dr Surjit Singh  
Consultant- Dr HPS Sachdev  
Consultant- Dr N. K. Arora  
Consultant- Dr Rajesh Kumar

Following were the special invitees who attended the meeting during their respective sessions only:

Dr. Pravin J. Mehta, Treasurer, Central IAP, Mumbai (attended whole meeting);  
Dr. Meenu Singh, PGI Chandigarh (attended whole meeting);  
Dr T. Jacob John,  
Dr. Ajay Khera, Dy. Commissioner (Child Health & Immunization), Ministry of Health & Family Welfare, GoI  
Dr. Suresh Jadhav, Executive Director, Serum Institute of India Ltd.

Dr. Prasad Kulkarni, Medical Director, Serum Institute of India Ltd.  
Mr. Raghu Reddy, Bharat Biotech  
Dr. Badri Patnaik, Bharat Biotech

1. Dr. C.P. Bansal, President IAP and Chairman ACVIP welcomed the Advisors and Experts of ACVIP and special invitees Dr. Meenu Singh. Dr. Bansal emphasized that all practitioners of immunization look forward to IAP guidelines which is rational, practical and evidence based. Committee members are selected through a democratic process. Dr. Bansal also said that members should declare their conflict of interest, if any and should not participate in discussion if there are conflicts.

Dr. Bansal then highlighted IDSurv with need for disease surveillance, and touched on the subject of evidence generation, mentioned about controversies related to IPV/OPV, pertussis, pentavalent vaccine. It is mentioned that few representatives from Indian manufacturers are invited and that there is need to promote Indian manufacturers judiciously.

2. Dr. Vipin M. Vashishtha, Convener of ACVIP, charted out issues for discussion. He mentioned that IAP has already prepared position paper on measles control strategies, AEFI, Influenza and pertussis which are either published or are under publication. On IAP Text book of Vaccines, Dr. Vipin mentioned that 95% of the chapters are completed and only Diphtheria and Hepatitis B remains to be completed. Review process remains the major concern and it is decided that timeline of 7 days may be given for completing the process.

It is decided not to accept financial support from any vaccine manufacturers for the publication of IAP Guide Book on Immunization and even for Evidence Based Review. It was discussed that publication may be entrusted to IAP publication house and that funds can be obtained from surplus funds of golden jubilee CME or utilize the grant from Emory received for a project earlier. Distribution modalities were also discussed but no firm conclusion could be made. It is decided to work on it later.

3. IAP website is being revamped and soon will be linked to the site being prepared by the vendor. ACVIP guidelines will be updated regularly in the manner done by WHO.

4. Self declaration form from each member was projected and the respective member was asked to comment on their disclosures. Other participants were also requested to point out any disparity observed

in the declarations. The issue was discussed in detail. A committee consisting of Dr. HPS Sachdev, Dr. A.K. Patwari and Dr. Shashi Vani was formed to go through the declaration forms and give opinion on it.

5. Dr. Vipin mentioned that he represented IAP in IEAG and meetings on Rotavirus and Pneumococcal vaccines organized by the DBT in Delhi.

6. Evidence based review (EBR) was discussed in great detail. Current requirement is mainly for disease burden, efficacy/effectiveness and safety related to rota, pneumo and Hib. Earlier efforts in this direction were discussed and subsequent discussion was on time line, need for grading, cost, funding options, *etc.* Dr. Meenu Singh and her team, from PGI are entrusted to formulate the modalities in this regard. PGI center already is working on some of the issues mentioned above on behalf of ICMR and Dr. Meenu Singh said this can be shared with IAP. Kind of support IAP can provide was discussed next. Though exact quantum of financial support needed could not be specified, Dr. Meenu Singh mentioned there is need to appoint research officers and that it could amount to Rs. 40, 000 per month as per ICMR pay scales. Need for soft ware and what is already available (related to efficacy and effectiveness) with the center was also discussed. A new working group of EBR members was proposed with members Dr. Panna Choudhury (Chair), Dr. Meenu Singh, Dr. Surjit Singh, Dr. A. K. Patwari, and Dr. Vipin M Vashishtha. It is suggested that for funding IAP can organized annual vaccine summit, and savings can be utilized for the purpose.

7. Detailed discussion was held on the issues of pentavalent safety and Hib disease burden. It was decided to issue an urgent, fresh press note and later a detailed rejoinder with a point-by-point rebuttal of the claims made by the author of IJME editorial (Dr AK. Patwari was entrusted with the responsibility of doing the needful).

8. It was decided to take up the issue of pre-exposure prophylaxis of rabies for the next meeting.

9. Representatives from Serum Institute of India made presentations on manufacturer's perspective on pentavalent vaccine; Representatives of Bharat Biotech made presentations on their upcoming vaccine like conjugated typhoid vaccine and new JE vaccine. They also provided some information on 116E rota vaccine to be marketed soon.

10. All the presentations were made as per agenda and Revised IAP Immunization Timetable was approved with following key changes:

- a. Changes in the recommendations of DTP approved
- b. Polio immunization schedule retained
- c. RV1 schedule revised from 6, 10 wk to 10, 14 wks
- d. New recommendations are suggested for JE, Meningococcal vaccination
- e. Info about few newer vaccines like JEEV, Typbar-TCV, Jenvac, was added
- f. Footnotes were revised and consolidated

Meeting ended with thanks to the Chair

Rapporteur: Dr Panna Choudhury

**Report prepared by Dr Panna Choudhury;**

**August 7, 2013, New Delhi**